中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

已收盘 05-21 16:08:15

5.280

+0.110

+2.13%

最高5.300	最低5.140	成交量6,942万
今开5.200	昨收5.170	日振幅3.09%
总市值989.74亿	流通市值989.74亿	总股本187.45亿
成交额3.65亿	换手率0.37%	流通股本187.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.28,"timestamp":1779350895003,"preClose":5.17,"halted":0,"volume":69422216,"delay":0,"changeRate":0.021276595744680913,"floatShares":18745000000,"shares":18745000000,"eps":0.14944351195205077,"marketStatus":"已收盘","change":0.11,"latestTime":"05-21 16:08:15","open":5.2,"high":5.3,"low":5.14,"amount":364553359,"amplitude":0.030948,"askPrice":5.28,"askSize":1211000,"bidPrice":5.27,"bidSize":55000,"shortable":3,"etf":0,"ttmEps":0.14944351195205077,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.17,"dividendRate":0.017045,"openAndCloseTimeList":[[1779327000000,1779336000000],[1779339600000,1779350400000]],"volumeRatio":0.906482,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.4426,"impliedVolPercentile":0.5142},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2637363933","title":"中国生物制药(01177)：宗艾替尼“HER2酪氨酸激酶抑制剂”一线HER2突变非小细胞肺癌适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637363933?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:36","pubTimestamp":1779366982,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团与勃林格殷格翰在中国大陆联合推广的圣赫途已获得中国国家药品监督管理局批准，单药适用于治疗存在HER2酪氨酸激酶结构域激活突变的不可切除的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。此次圣赫途一线适应症在中国获得附条件批准是基于1b期Beamion-LUNG 1队列2的临床试验结果，该试验评估了宗艾替尼在HER2激活突变的晚期非小细胞肺癌初治患者中的疗效和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","IE00BZ08YT58.USD","BK1191","IE00BZ08YR35.GBP","BK1521","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","BK1515","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137153576","title":"中国生物制药旗下佐格替尼获中国国家药监局批准用于HER2突变非小细胞肺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1137153576","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137153576?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:35","pubTimestamp":1779366906,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其创新药物佐格替尼已获得中国国家药品监督管理局批准，用于HER2突变型非小细胞肺癌的一线治疗。此项批准标志着公司在肿瘤治疗领域取得重要进展，有望为相关患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1589","BK1521","01177","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817579","title":"中国生物制药回购194万股 金额1003万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817579","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636817579?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:44","pubTimestamp":1779266640,"startTime":"0","endTime":"0","summary":"中国生物制药（01177）发布公告，2026年5月20日，公司回购股份194万股，回购金额为1003万港元。根据回购授权的决议，公司可回购的股份总数为18.76亿股，已回购股份5379万股，占回购授权决议通过时已发行股份的0.287%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743541158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK1191","BK1515","BK1589","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YT58.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130389558","title":"中国生物制药回购194万股股份，总额约1,002.53万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130389558","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130389558?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:42","pubTimestamp":1779266572,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年5月20日发布翌日披露报表。公告显示，2026年5月20日，公司在香港联交所场内回购了1,940,000股普通股，占公司现有已发行股份总数的比例约为0.01%。每股回购价介乎每股5.16港元至5.18港元，交易总金额约10,025,338港元，折合约1,002.53万港元。截至2026年5月20日，公司已发行股份总数仍为18,745,367,230股，库藏股数为0股。根据公告，该次回购股份将作注销处理，目前尚未注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药回购194万股股份，总额约1,002.53万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188349852","title":"中国生物制药：5月19日回购191万股，耗资约1,002.75万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188349852","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188349852?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:46","pubTimestamp":1779180409,"startTime":"0","endTime":"0","summary":"2026年5月19日，中国生物制药有限公司发布翌日披露报表。公告显示，公司于当日于香港联交所回购普通股1,910,000股，占已发行股本约0.01%。回购价格介乎每股5.24港元至5.26港元，合计耗资约1,002.75万港元。回购完成后，公司已发行股本保持18,745,367,230股，且无库藏股结存。根据公告，此次股份回购乃根据2025年6月10日通过的购回授权进行，目前公司可回购股份总数为1,876,071,723股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：5月19日回购191万股，耗资约1,002.75万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636839289","title":"中国生物制药(01177)5月19日斥资1002.75万港元回购191万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636839289","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636839289?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:43","pubTimestamp":1779180205,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，该公司于2026年5月19日斥资1002.75万港元回购191万股股份，每股回购价格为5.24-5.26港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01801","LU0326950275.SGD","01177","LU1152091168.USD","LU0348827113.USD","LU1226288170.HKD","LU0634319403.HKD","LU1993786604.SGD","LU2097828631.EUR","LU1226287792.SGD","06160","LU0067412154.USD","IE00B031HY20.USD","09688","LU0456846285.SGD","LU0572944931.SGD","09926","LU0516422952.EUR","LU1719994722.HKD","02616","06978","BK1161","159992","LU1152091754.HKD","LU1880383366.USD","SG9999002562.SGD","ARTY","LU1303224171.USD","09995","AGIX","LU0072913022.USD","01093","LU1960683339.HKD","02142","IE00BPRC5H50.USD","LU0315179316.USD","BK1583","BK1588","02269","LU0348767384.USD","AIPO","LU0856984785.SGD","LU0140636845.USD","LU0456827905.SGD","01877","CHAT","LU0417516738.SGD","06185","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636959000","title":"中国生物制药(01177)股东将股票存入兴业银行 存仓市值32.34亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636959000","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636959000?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:17","pubTimestamp":1779149861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月18日，中国生物制药(01177)股东将股票存入兴业银行，存仓市值32.34亿港元，占比3.2%。中国生物制药(01177)发布公告，于2026年5月18日斥资1000.34万港元回购189万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","LU0572940350.SGD","601166","LU1781817850.SGD","LU0264606111.USD","BK0183","LU0572939691.SGD","BK0187","LU0821914370.USD","LU1048596156.SGD","BK1589","LU1328615791.USD","BK0028","BK0012","BK0015","BK1191","IE00BZ08YS42.EUR","HK0000181138.USD","01177","IE00BZ08YR35.GBP","BK0278","BK1521","BK0188","LU1580142542.USD","BK1515","HK0000181112.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109194026","title":"中国生物制药回购189万股股份，耗资约1000.34万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109194026","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109194026?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:32","pubTimestamp":1779093155,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年5月18日发布公告，披露于当日回购普通股股份189万股，占公司当日已发行股本约0.01%。本次回购股份每股价格介乎港币5.27至5.31元不等，合计耗资约1000.34万港元。是次回购在香港联交所场内进行。公告显示，本次回购完成后，公司已发行股本总数仍为187.4536723亿股，暂未注销或转换为库藏股。公司购回授权于2025年6月10日获得股东会通过，根据授权可回购最多18.76071723亿股。公司确认上述回购行为符合香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"497fd758b38c276bd0bec58e92fb66d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药回购189万股股份，耗资约1000.34万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636025812","title":"中国生物制药(01177)5月18日斥资1000.34万港元回购189万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636025812","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636025812?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:29","pubTimestamp":1779092951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年5月18日斥资1000.34万港元回购189万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"497fd758b38c276bd0bec58e92fb66d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1589","BK1515","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1969619763.USD","SG9999002562.SGD","LU1688375341.USD","02616","09926","01177","LU0417516738.SGD","09688","IE00B0JY6N72.USD","IE00BZ08YR35.GBP","06185","LU1226287875.USD","BK1588","LU0348827113.USD","06978","IE00B543WZ88.USD","LU0561508036.HKD","LU0326950275.SGD","LU1242518857.USD","02269","LU0588546209.SGD","01801","LU0979878070.USD","LU0516422952.EUR","01877","BK1141","LU2097828631.EUR","601066","LU1303224171.USD","01093","159992","LU1152091168.USD","LU1242518931.SGD","09995","LU2097828474.EUR","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","BK1574","LU0359202008.SGD","BK1161","LU1993786604.SGD","LU2399975544.HKD","IE00BZ08YS42.EUR","LU0456827905.SGD","LU0039217434.USD","LU1152091754.HKD","LU2097828557.USD","02142","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177102281","title":"中国生物制药回购187万股股份，总金额约1002.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177102281","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177102281?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:42","pubTimestamp":1778834544,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年5月15日发布翌日披露报表。公告显示，公司于当日回购股份187.00万股，占公司现有已发行股本的0.01%，回购价区间为每股5.35港元至5.37港元，总涉资约1002.69万港元。回购完成后，公司已发行股本仍为187.45亿股，库藏股余额为0股。相关数据显示，公司可根据该购回授权购回股份总数为18.76亿股，截至目前，合计已回购4805.00万股，约占授权通过日已发行股本的0.256%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药回购187万股股份，总金额约1002.69万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704498","title":"中国生物制药(01177)5月15日斥资1002.69万港元回购187万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704498","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635704498?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:38","pubTimestamp":1778834297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年5月15日斥资1002.69万港元回购187万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1589","BK1515","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144820517","title":"中国生物制药5月14日回购182万股，耗资约1,003.64万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144820517","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144820517?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:42","pubTimestamp":1778748121,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年5月14日发布翌日披露报表。公告显示，公司在香港联交所场内回购182万股普通股，占2026年5月13日已发行股本约0.01%，回购价格介乎每股5.51港元至5.52港元，涉资约1,003.64万港元。回购完成后，公司已发行股本依旧为18,745,367,230股，库藏股为0股。本次回购前，公司已根据该授权累计回购46,180,000股，占授权通过日已发行股本总数的约0.246%。公司同时确认，其回购交易及本次信息披露均符合香港联合交易所证券上市规则等有关法例及规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药5月14日回购182万股，耗资约1,003.64万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792654","title":"中国生物制药(01177)5月14日斥资1003.64万港元回购182万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792654","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792654?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:37","pubTimestamp":1778747876,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，该公司于2026年5月14日斥资1003.64万港元回购182万股股份，每股回购价格为5.51-5.52港元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)5月14日斥资1003.64万港元回购182万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","BK1191","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YR35.GBP","01177","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635768379","title":"中国生物制药附属减肥创新药亮相欧洲大会：体外活性提升10倍以上，联合用药脂肪减少量提高1.5-2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2635768379","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635768379?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:53","pubTimestamp":1778719980,"startTime":"0","endTime":"0","summary":"5月14日，中国生物制药（01177）发布公告，本公司附属公司正大天晴药业集团股份有限公司自主开发的创新药TQF6422“ActRIIA/B单抗”临床前研究数据已于2026年欧洲肥胖大会（ECO）公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143736704546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","01177","BK1191","BK1589","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","06978","BK1515","BK1521","BK1161","IE00BZ08YT58.USD","HK0000165453.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635590754","title":"中国生物制药(01177)：TQF6422“ACTRII A/B单抗”最新研究数据于2026 ECO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2635590754","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635590754?lang=zh_cn&edition=full","pubTime":"2026-05-14 06:48","pubTimestamp":1778712536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，集团附属公司正大天晴药业集团股份有限公司(“正大天晴”)自主开发的创新药TQF6422“ActRII A/B单抗”临床前研究数据已于2026年欧洲肥胖大会(ECO)公布。TQF6422是一款靶向ActRII A/B的全人源单克隆抗体，通过特异性结合ActRII A/B受体并阻断其配体(Activin、Myostatin)介导的信号转导，在促进骨骼肌生长的同时增强脂肪分解，从而实现减脂增肌的双重效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4144","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","ECO","IE00BZ08YR35.GBP","LU0997586861.USD","BK1521","HK0000165453.HKD","BK1589","BK1191","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106660920","title":"中国生物制药5月13日回购178万股，涉资约1005.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106660920","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106660920?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:37","pubTimestamp":1778661421,"startTime":"0","endTime":"0","summary":"中国生物制药（01177）于2026年5月13日公告，公司于当日在香港联交所场内回购普通股1,780,000股，占公司于交易日前已发行股本的约0.009%。回购价格介乎每股5.64港元至5.65港元，合共耗资10,052,016港元，折合约1,005.20万港元。\n本次回购完成后，公司已发行股本总数仍为18,745,367,230股，库藏股数目无变化。根据购回授权，公司原可回购1,876,071,723股，迄今已合共回购44,360,000股，相当于授权通过时已发行股份总数约0.236%。公司表示，已遵守《香港联合交易所有限公司证券上市规则》等相关法律法规。\n本公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药5月13日回购178万股，涉资约1005.20万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635201012","title":"中国生物制药(01177)5月13日斥资1005.2万港元回购178万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635201012","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635201012?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:34","pubTimestamp":1778661265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年5月13日斥资1005.2万港元回购178万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1521","01177","IE00BZ08YT58.USD","BK1589","HK0000165453.HKD","BK1515","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634683261","title":"港股异动 | 中国生物制药(01177)涨超3% 高盛指引入bepirovirsen疗法有望升级公司肝炎产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2634683261","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634683261?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:43","pubTimestamp":1778564586,"startTime":"0","endTime":"0","summary":"根据协议，公司将利用其领先的肝炎基础设施，全面负责进口、分销、医院准入及推广，并将全数录入bepirovirsen在中国的销售。报告指出，bepirovirsen作为针对慢性乙肝功能性治愈的同类首创疗法，策略上契合中国7,500万慢性乙肝患者的治疗重点，有望升级中国生物制药的肝炎产品组合。该行估计bepirovirsen的潜在销售额高峰约为50亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4127","IE00BFXG1179.USD","HK0000165453.HKD","LU0345770308.USD","LU1868836914.USD","LU0096364046.USD","BK4550","LU1804176565.USD","LU1668664300.SGD","GSX","LU0251142724.SGD","LU2471134523.USD","IE00BZ08YT58.USD","LU0742534661.SGD","IE0002270589.USD","LU2471134796.USD","LU1868837300.USD","BK4533","LU0061475181.USD","BK4585","IE0004091025.USD","LU2237443549.SGD","LU2237443382.USD","LU1791807156.HKD","LU2265009873.SGD","BK4516","LU2471134952.CNY","IE00BZ08YR35.GBP","BK4504","LU2750360997.AUD","IE0004086264.USD","LU1894683348.USD","LU1868836591.USD","IE00B19Z3581.USD","LU2237443978.SGD","IE00BZ08YS42.EUR","LU1868836757.USD","IE00BSNM7G36.USD","BK1521","IE00B19Z3B42.SGD","01177","BK4588","LU2237443895.HKD","VXUS","LU0106831901.USD","BK4552","LU1894683264.USD","LU2237443622.USD","LU0251131958.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.085},{"period":"1month","weight":-0.1311},{"period":"3month","weight":-0.2083},{"period":"6month","weight":-0.2397},{"period":"1year","weight":0.2539},{"period":"ytd","weight":-0.1634}],"compareEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0395},{"period":"6month","weight":0.0171},{"period":"1year","weight":0.0832},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.478261,"avgChangeRate":0.021296},{"month":5,"riseRate":0.695652,"avgChangeRate":0.039457},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}